Many drugs work by binding to a protein and blocking it. Technology for eliminating disease-causing proteins altogether remains experimental, but this approach has gained ground in the past year with hundreds of millions of dollars raised and compounds advanced into clinical testing. Monte Rosa is one of the newer companies in this “protein degradation” space and it has secured $96 million in financing as it looks to bring its first compound into human testing next year.
The Series B round of funding announced Thursday was led by Aisling Capital.
Targeted protein degradation involves using a cell’s built-in system for recycling old… Read more »
UNDERWRITERS AND PARTNERS